Scientific Peptide Dosage Charts & Reconstitution Protocols
Peer-reviewed dosing schedules, titration charts, and reconstitution math for 173 research peptides — from Retatrutide and Tirzepatide to BPC-157, Selank, and SS-31.
Browse by category
173 protocols across 10 therapeutic categories.
Anabolics
7Androgenic-anabolic support, muscle density, and receptor modulation.
Weight Loss
33GLP-1 agonists, GIP analogues, and metabolic agents for fat oxidation.
Growth Hormone
25Secretagogues and growth-hormone-releasing peptides for cell regeneration.
Healing & Recovery
16BPC-157, TB-500, and extracellular matrix remodeling factors.
PCT & Ancillaries
8Aromatase inhibitors, prolactin control, and endocrine restoration.
Cognitive
18Nootropic peptides, neuropeptides, and nerve growth factors (BDNF/NGF).
Longevity
32Telomerase activators, senolytic peptides, and cellular bioregulators.
Skin & Hair
19Melanocortin agonists and collagen-remodeling copper peptides.
Immune
9Thymic peptides, immunomodulators, and antimicrobial defenses.
Metabolic
6AMPK activators, cardiolipin stabilizers, and metabolic rate enhancers.
Popular protocols
Frequently referenced dosage charts. Use the search or a category above to reach any of the 173.
Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk and marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral T2D). In the pivotal Phase 3 STEP-1 trial of 1,961 adults with overweight or obesity without diabetes, weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo, with 86% of treated participants achieving at least 5% loss [1]. Semaglutide is FDA approved for T2D (Ozempic, 2017), chronic weight management (Wegovy, 2021) and cardiovascular risk reduction in adults with obesity and established CVD (Wegovy expansion, 2024 — based on SELECT). Standard dosing is a 16-week titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, increasing every 4 weeks.
Cagrilintide + Semaglutide
CagriSema is the fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), both at 2.4 mg weekly, developed by Novo Nordisk and submitted to the FDA in December 2025 based on the Phase 3 REDEFINE-1 trial. The combination exploits complementary satiety pathways: cagrilintide engages amylin/calcitonin-receptor signaling in the brainstem while semaglutide acts on hypothalamic GLP-1 receptors — producing an additive rather than redundant effect on appetite suppression and weight loss. In REDEFINE-1, CagriSema 2.4/2.4 mg weekly produced 22.7% mean weight loss at 68 weeks compared to 11.8% with cagrilintide alone, 16.1% with semaglutide alone, and 2.3% with placebo [1]. CagriSema is not yet FDA approved (NDA review expected to complete in 2026). Standard dosing escalates both peptides in parallel through a 16–20 week titration to the 2.4 mg / 2.4 mg maintenance dose.
Tirzepatide
Tirzepatide is a once-weekly synthetic 39-amino-acid peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, manufactured by Eli Lilly and marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In the Phase 3 SURMOUNT-1 trial of 2,539 adults without diabetes, tirzepatide 15 mg weekly produced a mean body-weight reduction of 20.9% at 72 weeks versus 3.1% with placebo, with 57% of participants losing at least 20% of body weight [1]. FDA approval for type 2 diabetes was granted in May 2022 and for chronic weight management in November 2023; tirzepatide is approved in the EU, UK, Japan, China and most major markets. Doses escalate monthly from 2.5 mg up to 5, 7.5, 10, 12.5 and a 15 mg maintenance ceiling.
Retatrutide
Retatrutide (LY3437943) is a once-weekly triple-receptor agonist that activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors in a single peptide backbone, combining appetite suppression with thermogenic energy expenditure. In the Phase 2 TRIUMPH-2 trial published in NEJM, adults with obesity receiving 12 mg weekly achieved a placebo-adjusted mean weight reduction of 24.2% at 48 weeks, the largest pharmacologic weight loss reported to date and with no apparent plateau on the dose-response curve [1]. The 9 mg and 12 mg arms of the Phase 3 TRIUMPH-4 trial confirmed up to 28.7% weight reduction in adults with obesity and knee osteoarthritis at 68 weeks [2]. Retatrutide is investigational, not FDA approved, and remains restricted to clinical-trial use; it is sold by chemical suppliers as a research compound only.
Mazdutide
Mazdutide (IBI362, LY3305677) is a once-weekly dual glucagon-receptor and GLP-1 receptor agonist engineered as an analogue of the endogenous gut hormone oxyntomodulin. It was originally discovered by Eli Lilly, then out-licensed to Innovent Biologics for development across Greater China and other Asian markets. In the Phase 3 GLORY-1 trial of Chinese adults with overweight or obesity, mazdutide 6 mg weekly produced a mean body-weight reduction of 14.0% at 48 weeks, with 49.5% of participants losing at least 15% of body weight versus 2.0% on placebo [1]. Mazdutide is investigational in the United States and most of Europe but received its first NDA acceptance from China's NMPA in February 2024 for chronic weight management — approval is anticipated in 2025–2026. Standard dosing escalates from 1.5 mg weekly to 3, 4.5, 6 and up to 9 mg over 12–16 weeks.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.
BPC-157 + TB-500
The BPC-157 and TB-500 stack pairs two research peptides with complementary regenerative mechanisms: BPC-157 (Body Protection Compound, a 15-amino-acid pentadecapeptide from gastric juice that drives VEGFR2-mediated angiogenesis and growth hormone receptor upregulation in tendon fibroblasts) [1][2] and TB-500 (the active 7-amino-acid fragment of thymosin beta-4 that sequesters G-actin, promotes endothelial cell migration, and supports stem cell mobilization) [3][4]. Sikiric, Chang, and colleagues have published the preclinical foundations for BPC-157 in tendon, ligament, and gastrointestinal healing, while Goldstein, Crockford, and colleagues have established TB-500/thymosin beta-4 in wound, cardiac, and corneal repair [5][6]. The combination is not FDA approved, and the only published controlled clinical evidence on each peptide individually is limited. Typical research dosing pairs BPC-157 at 250 to 500 mcg/day subcutaneously with TB-500 at 2 to 5 mg twice weekly during a 4 to 6 week loading phase, followed by maintenance of TB-500 at 2 mg weekly for an additional 4 to 8 weeks.
TB-500 + BPC-157
The TB-500 and BPC-157 stack is the most widely studied combination protocol in unregulated peptide research, pairing two regenerative peptides with distinct loading and maintenance dosing schedules designed to match the very different pharmacokinetic profiles of the two molecules and the different tissue compartments their mechanisms address [1][2][3]. TB-500 (the active fragment of thymosin beta-4) has a plasma half-life of approximately 2 hours but durable tissue incorporation that supports twice-weekly dosing during loading and once-weekly maintenance [4][5]. BPC-157 (the gastric pentadecapeptide originally isolated by Sikiric and colleagues) is unusually stable in serum and gastric juice and is typically given as small daily injections to maintain steady angiogenic and growth factor signaling at the site of injury throughout the cycle [6][7]. Goldstein, Crockford, Sikiric, Chang, and colleagues provide the preclinical evidence base for each component [4][5][6][8]. The combination is not FDA approved and is banned in competitive sport by WADA under category S2. This page focuses on dosing-schedule architecture (loading, maintenance, taper, cycling, injection-site selection) rather than re-derivation of basic mechanism, which is covered in the BPC-157 plus TB-500 page.
TB-500
TB-500 is the synthetic counterpart of the active region of thymosin beta-4 (Tbeta4), a 43-amino-acid G-actin-sequestering peptide first isolated by Allan Goldstein and colleagues from bovine thymus tissue in the 1960s [1][2]. Goldstein and Crockford have published extensively on Tbeta4's roles in actin polymerization regulation, endothelial cell migration, angiogenesis, anti-inflammatory signaling, and stem cell mobilization, with downstream effects on wound healing, cardiac repair, and corneal regeneration [3][4]. Phase 2 trials of topical thymosin beta-4 in venous stasis ulcers and pressure ulcers showed accelerated healing in subsets of patients, with safety comparable to placebo, although the trials had small sample sizes and methodological constraints [5][6]. TB-500 is not approved by the FDA, EMA, or other Western regulators for any indication; it remains a research peptide and is banned by WADA for athletes. Research dosing in animals and the human literature typically uses 2 to 10 mg/week subcutaneously, often split into one or two injections during a 4 to 6 week loading phase, followed by maintenance at 2 mg/week.
Reference guides
Deep-dives on safety, reconstitution, storage, and syringe reading.
Beginner's Guide
Fundamental biology, pathways, and core terminology of peptides.
Read guidearrow_forwardscienceReconstitution Guide
How to measure, inject, and preserve lyophilized peptides.
Read guidearrow_forwardac_unitStorage & Cold Chain
Temperature ranges, light protection, and shelf-life metrics.
Read guidearrow_forwardvaccinesSyringe Measurements
Decoding U-100 markings, ticks, and volumetric conversions.
Read guidearrow_forward